Mayne will regain favour soon enough. a few product approvals like today will help fund managers see through whether eanrings are 1-2% above or below forecast and will focus on the eanrings growth potential of this company
A healthcare stock with a PE of under 11, low debt, diversifed with significant earnings grow, is a steal
worth at least 1.50 -170 imo
Ann: FDA approval and first generic launch of Acticlate tablets, page-22
Add MYX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$4.26 |
Change
0.090(2.16%) |
Mkt cap ! $362.4M | |||
| Open | High | Low | Value | Volume |
| $4.15 | $4.34 | $4.15 | $939.1K | 220.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 171 | $4.23 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $4.27 | 1207 | 2 |
View Market Depth
| Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
| MYX (ASX) Chart |